ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 1.5B 3B 4.5B FY08: 96.2M FY09: 100.5M FY10: 100M FY16: 47.2M FY17: 89.9M FY18: 74.9M FY19: 219.8M FY20: 492.9M FY21: 844.3M FY22: 1B FY23: 1.8B FY24: 2.2B FY25: 3.7B FY08 FY10 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-1.1B -700M -350M 0 350M 700M 1.1B FY08: -27.8M FY09: -48.1M FY10: -44.1M FY11: -54.8M FY12: -129.5M FY13: -92.9M FY14: -405M FY15: -296M FY16: -424.6M FY17: -500.1M FY18: -814.7M FY19: -939.4M FY20: -828.4M FY21: -708.7M FY22: -785.1M FY23: -282.2M FY24: -176.9M FY25: 501.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-1.2B -800M -400M 0 400M 800M 1.2B FY08: -26.2M FY09: -47.6M FY10: -43.5M FY11: -57.6M FY12: -106M FY13: -89.2M FY14: -360.4M FY15: -290.1M FY16: -410.1M FY17: -490.9M FY18: -761.5M FY19: -886.1M FY20: -858.3M FY21: -852.8M FY22: -1.1B FY23: -440.2M FY24: -278.2M FY25: 313.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 250M 500M 750M FY17: 0 FY18: 1.8M FY19: 25.1M FY20: 74.2M FY21: 115M FY22: 140.2M FY23: 268.2M FY24: 306.5M FY25: 677.2M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-750M -500M -250M 0 250M 500M 750M FY08: 65.5M FY09: -72.1M FY10: -84.3M FY11: -87.1M FY12: -115.6M FY13: -68.7M FY14: -165.6M FY15: -189.1M FY16: -307.7M FY17: -382.8M FY18: -562.6M FY19: -278.4M FY20: -615M FY21: -641.7M FY22: -541.3M FY23: 104.2M FY24: -8.3M FY25: 524.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-750M -500M -250M 0 250M 500M 750M FY08: 54.7M FY09: -77.1M FY10: -89.1M FY11: -88.4M FY12: -124M FY13: -72.7M FY14: -174.6M FY15: -202.1M FY16: -372.3M FY17: -487M FY18: -689.5M FY19: -418.6M FY20: -685.3M FY21: -718.1M FY22: -613.3M FY23: 41.9M FY24: -42.6M FY25: 465.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 50M 100M 150M FY19: 109.3M FY20: 115M FY21: 118.5M FY22: 121.7M FY23: 124.9M FY24: 127.7M FY25: 134.7M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '10: -1.04 Q1 '11: -1.13 Q2 '11: -1.11 Q3 '11: -1.19 Q4 '11: -1.35 Q1 '12: -1.22 Q2 '12: -1.14 Q3 '12: -1.21 Q4 '12: -2.08 Q1 '13: -1.98 Q2 '13: -2.02 Q3 '13: -2.12 Q4 '13: -1.43 Q1 '14: -4.98 Q2 '14: -5.27 Q3 '14: -5.37 Q4 '14: -5.14 Q1 '15: -2.06 Q2 '15: -2.33 Q3 '15: -2.66 Q4 '15: -3.45 Q1 '16: -4.04 Q2 '16: -4.24 Q3 '16: -4.54 Q4 '16: -4.79 Q1 '17: -4.83 Q2 '17: -5.12 Q3 '17: -5.25 Q4 '17: -5.41 Q1 '18: -5.57 Q2 '18: -5.86 Q3 '18: -6.95 Q4 '18: -7.56 Q1 '19: -7.88 Q2 '19: -8.27 Q3 '19: -7.76 Q4 '19: -8.14 Q1 '20: -8.03 Q2 '20: -7.57 Q3 '20: -7.83 Q4 '20: -7.45 Q1 '21: -7.54 Q2 '21: -7.59 Q3 '21: -7.13 Q4 '21: -7.20 Q1 '22: -7.49 Q2 '22: -8.17 Q3 '22: -9.77 Q4 '22: -9.29 Q1 '23: -8.69 Q2 '23: -8.61 Q3 '23: -4.14 Q4 '23: -3.55 Q1 '24: -2.67 Q2 '24: -0.59 Q3 '24: -2.61 Q4 '24: -2.17 Q4 '10 Q4 '12 Q4 '14 Q4 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.